Remicade Biosimilars Market

Remicade Biosimilars Market - Size, Share, Outlook,
and Opportunity Analysis, 2018-2026
Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and
safety to an existing licensed reference therapeutic drug. Biological products are the fastest
growing class of therapeutic products, as they offer additional treatment options and help in
lowering healthcare costs. Biosimilars are almost identical copies of the originally approved
drugs and can be manufactured only when the patent for the original innovator drug expires.
These products are highly sensitive to smallest changes in manufacturing procedure, as these
drugs possess high molecular complexity. Remicade (Infliximab) refers to a chimeric monoclonal
antibody biologic licensed by U.S. FDA in 1998, as an innovative product indicated for the
treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first
developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later
approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis,
and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical
manufacturers developed biosimilars to infliximab, which lowered market share of Remicade
due to cost-effective prices.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1769
Market Dynamics
Increasing incidence of autoimmune diseases such as plaque psoriasis and rheumatoid
arthritis are expected to drive growth of the Remicade biosimilar market size. According
to the American Autoimmune Related Disease Association, around 50 million American
suffered from autoimmune diseases in the U.S. in 2017. Moreover, faster reaction rates
of these biosimilars due to their availability in the form of intravenous mode of
administration is further expected to increase the adoption of Remicade biosimilar over
the forecast period. Furthermore, patent expiry of the branded versions is expected to
increase the number of biosimilars for its branded counterparts thereby increasing the
demand for Remicade biosimilar. However, stringent regulatory guidelines for
development of these biosimilars as well as side effects of these drugs leading to risk of
hospitalization are expected to restrain growth of the global Remicade biosimilar market.
Report includes chapters which deeply display the following deliverable about industry :
• Remicade Biosimilars Market Research Objective and Assumption
• Remicade Biosimilars Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Remicade Biosimilars Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Remicade Biosimilars Market, By Regions
• Remicade Biosimilars Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Remicade Biosimilars Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Remicade Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Remicade Biosimilars Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Regional Insights
On the basis of region, the global Remicade biosimilar market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe holds a dominant position
in the global Remicade biosimilar market and is expected to retain its dominance over the
forecast period, owing to the presence of top market players in the region, rapid entry of
biosimilars in the European market as well as high adoption rate due low price of the
biosimilars. For instance, in 2018, Sandoz, a Novartis division received European Commission
(EC) approval for Zessly (infliximab) a remicade biosimilar for use in Europe. The successive
research and speedy approvals by the U.S. regulatory authorities for market entry of biosimilars
in North America is expected to drive growth of the market over the forecast period. For
instance, in December 2017, Pfizer, Inc. received the U.S. FDA approval for second biosimilar,
Ifixi to Janssen’s blockbuster drug Remicade to treat rheumatoid arthritis.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1769
Competitive Landscape
Key players operating in the global remicade biosimilar market include Janssen Biotech, Inc.,
Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp
Pharmaceuticals, and others. Market players are focused on introducing maximum number of
biosimilar for multiple indications to retain their position in the global market. For instance, in
July 2017, Merck & Company, Inc. in collaboration with Samsung Bioepis introduced Renflexis
(infliximab-abda), a biosimilar to Remicade for the treatment of moderate to severe Crohn’s
disease, active ulcerative colitis, rheumatoid arthritis, and other few disease indications.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and safety to an existing licensed reference therapeutic drug.